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Abstract 
Background and purpose: Coronary artery disease leads to ischaemic heart disease 
and ultimately myocardial infarction. Thus is it important to determine the factors that 
regulate coronary blood flow. Ca2+-activated chloride channels contribute to the 
regulation of arterial tone; however, their role in coronary arteries is unknown. The 
aim of this study was to investigate the expression and function of the main 
molecular correlate of Ca2+-activated chloride channels, TMEM16A, in rat coronary 
arteries. 
Experimental approach: We performed mRNA and protein analysis, 
electrophysiological studies of coronary artery myocytes, and functional studies of 
coronary artery contractility and coronary perfusion, using novel inhibitors of 
TMEM16A. Furthermore, we assessed whether any changes in expression and 
function occurred in coronary arteries from spontaneously hypertensive rats. 
Key Results: TMEM16A was expressed in rat coronary arteries. The TMEM16A-
specific inhibitor, MONNA, hyperpolarised the membrane potential by -22.1mV in 
U46619, (p=0.0017). MONNA, T16Ainh-A01, and Ani9 attenuated 5HT/U46619-
induced contractions, and MONNA and T16Ainh-A01 also increased coronary flow in 
Langendorff perfused rat heart preparations (p=<0.0001 for both drugs). TMEM16A 
mRNA was increased in coronary artery smooth muscle cells from spontaneously 
hypertensive rats (SHR), and U46619/5HT were more potent in arteries from SHRs 
(5HT EC50  in Wistars was 207r56 nM, versus 51r16 nM in SHRs, n=12 and n=13 
respectively, p<0.05). MONNA diminished this increased sensitivity to U46619 and 
5HT.  
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Conclusions and Implications: In conclusion TMEM16A is a key regulator of coronary 
blood flow and is implicated in altered contractility of coronary arteries from SHRs. 
Abbreviations: 
ACTA2   Actin alpha 2 smooth muscle 
ANOVA   Analysis of Variance 
ATP5B   ATP Synthase subunit Beta, mitochondrial 
CaCC    Calcium-activated chloride channel 
CADD    Combined annotation dependent depletion 
CFTR    Cystic fibrosis transmembrane conductance regulator 
CYC1    Cytochrome C1 
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
GFP    Green fluorescent protein 
ICl    Chloride current 
ICl(Ca)    Calcium-activated chloride current 
LAD    Left anterior descending (coronary artery) 
LCPSS   Low chloride physiological saline solution 
Myh11   Myosin Heavy Chain 11 
Pecam1   Platelet and endothelial cell adhesion marker 1 
PSS    Physiological saline solution    
ROCK    Rho-associated protein kinase 
SEM    Standard error of the mean 
SHR    Spontaneously hypertensive rat 
SNP    Single nucleotide polymorphism 
Tnni3    Troponin I3 
Tnnt2    Troponin T2 
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VGCC    Voltage-gated calcium channel 
VSMC    Vascular smooth muscle cell 
Vwf    Von Willebrand Factor 
YWHAZ   14-3-3 protein zeta/delta 
5HT    5 hydroxytryptamine 
What is already known: 
x TMEM16A proteins contribute to calcium-activated chloride channels. 
x Reducing TMEM16A activity reduces vasoconstriction in pulmonary and 
mesenteric arteries. 
What this study adds: 
x TMEM16A blockers impaired vasoconstrictor responses in coronary artery 
and improved coronary blood flow. 
x Coronary arteries from hypertensive rats exhibited raised TMEM16A and 
augmented vasoconstrictor sensitivity. 
Clinical Significance: 
x Targeting TMEM16A represents a new therapeutic target for ischaemic heart 
disease 
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CaCC - http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=130 
 
U46619 - 
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1888 
 
5HT - http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5 
 
VGCC - http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=80 
 
Nicardipine - 
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2559 
 
Caffeine - 
http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=407 
 
CFTR - http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707 
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channels, blood flow, SHR, T16inh-A01, MONNA.  
 
Introduction 
Coronary artery disease occurs when the narrowing of coronary arteries prevents 
sufficient cardiac perfusion. If left untreated, it can cause fatal myocardial infarctions. 
High blood pressure is a major risk factor for coronary artery disease, and reducing 
blood pressure is one of the best treatments to reduce or prevent coronary events. 
Cardiac perfusion is determined by flow through the coronary arteries, which is 
determined by the contractile state of the vascular smooth muscle cells as well as 
the presence of pathological impediments like atheroma or thrombi. Understanding 
what controls coronary artery smooth muscle contraction is necessary to 
comprehend what limits cardiac perfusion and to develop novel therapies.  
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TMEM16A (also known as ANO1) proteins contribute to the formation of chloride 
permeable channels that are activated by sub-micromolar concentrations of 
intracellular calcium (CaCCs). As vascular smooth muscle cells (VSMCs) actively 
accumulate chloride ions (Cl-), activating CaCCs leads to Cl- efflux and membrane 
depolarisation sufficient to activate VGCCs, and evoke contraction. Consequently, 
TMEM16A represents a possible factor in the development of vascular disease 
including hypertension and targeting these channels may be a viable new therapy. 
Whilst TMEM16A expression has been identified in several arteries (Dam et al., 
2014; Davis et al., 2010; Manoury et al., 2010; Thomas-Gatewood et al., 2011) there 
is no data on TMEM16A in coronary arteries and whether it is altered in 
hypertension. Moreover, there is no information on the effect of recently developed 
TMEM16A-specific blockers in coronary arteries. The present study sought to 
address these points.  
 
Methods 
Animals: All experiments were performed on 1st and 2nd order branches of the left 
anterior descending coronary artery (LAD) and 1st order septal coronary arteries or 
3rd order mesenteric arteries from male Wistar rats (aged 12-13 weeks, weighing 
250-350g) (Charles River, Margate, UK) (RRID:RGD_737929), killed by cervical 
dislocation in accordance with schedule 1 of the UK Animal (Scientific Procedures) 
Act 1986. Spontaneously hypertensive rats (SHRs) (Envigo, UK) 
(RRID:RGD_724574)  aged 12-13 weeks (weighing 250-300g) were used as an 
acknowledged model of essential hypertension. Rats were housed according to 
ASPA 1986 regulations with  12:12 hour light:dark cycle; 19-22 centigrade room 
temperature; room relative humidity within a range of 50% +/- 10%; received ad 
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libidum water (changed at least twice weekly) and laboratory rodent diet. Bedding 
was LBS Aspen Classic woodchip. Coronary arteries were identified and dissected 
free of the heart. The pericardium was peeled away from the surface of the heart and 
the right and left main coronary arteries were traced from the aortic root. Arteries 
were dissected free from myocardial tissue before they were used in any experiment. 
The LAD was identified as the main artery distal to the bifurcation at the left 
circumflex artery. The septal artery was identified by cutting away the right 
ventricular wall whence it could be seen running along the interventricular septum. 
The septal artery varied in its anatomical origin, sometimes arising from the right 
coronary artery and sometimes from the left.  
 
Expression Studies: The expression of TMEM16A, as well as the reference genes 
ATP synthase subunit beta (ATP5B), cytochrome C1 (CYC1), 14-3-3 protein 
zeta/delta (YWHAZ), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
(predetermined by GeNorm (Biogazelle, Belgium) analysis) was measured by 
quantitative polymerase chain reaction (QPCR). The coronary artery SMC samples 
were obtained by cutting longitudinally along the dissected vessel and rubbing the 
lumen with a human hair. The vessel was then placed in 0.1% Triton X PBS for 1 
minute followed by three 1 minute washes in fresh PBS to ensure removal of 
endothelium. The treated arteries were subsequently dispersed to a cell suspension 
as outline below before being spun down into a pellet and used for RNA extraction. 
Cardiac- and endothelial-cell specific primers were designed to check for 
contamination of the SMC sample. For a full list of primers used in this study see 
table 1. The primer sequences for housekeeping genes used for the GeNorm were 
unavailable due to proprietary reasons. QPCR samples were run in duplicate to 
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strengthen the reliability of the single value. Antibody AB53212 (AbCam, Cambridge, 
UK), used in previous studies (Pritchard et al., 2014) was used for immunochemical 
and Western blot studies (Abcam Cat# ab53212, RRID:AB_883075). 
  
Functional studies. Wire myography was used to assess TMEM16A function in 
LAD coronary artery segments. Once the LAD coronary artery had been dissected 
free from surrounding cardiac tissue, segments were mounted onto the myograph 
(Danish MyoTech, Aarhus, Denmark) in PSS. The force on elicited by the tension of 
the vessel wall on the wires was recorded using LabChart software (ADInstruments, 
UK). For simultaneous membrane potential recordings, coronary artery segments 
were impaled with sharp glass microelectrodes with resistances of 60-130 M:, 
pulled on a horizontal puller (P-97 Sutter Instrument Co., USA), that were filled with 
3M KCl. The reference electrode (flat-tip Ag/AgCl probe; Warner Instrument, USA) 
was submerged into the myograph chamber and the amplifier was zeroed with the 
recording electrode lowered into the bath solution. Voltage was recorded at 1 kHz 
through an amplifier (Intra 767, WPI Ltd.) and A-D converter (PowerLab 4SP, 
ADInstruments, New Zealand). Impalements were deemed suitable when there was 
an abrupt, negative deflection in potential which rapidly returned to the pre-
impalement level upon withdrawal from the cell. In both settings the vessel segments 
were bathed in PSS (in mM: NaCl 119, KCl 4.5, MgSO47H2O 1.17, NaH2PO42H2O 
1.18, NaHCO3 25, Glucose 5, CaCl2 1.25), heated to 37qC and aerated with 95% O2, 
5% CO2. 
For Langendorff studies, hearts were swiftly dissected and the ascending aorta was 
tied onto a perfusion cannula attached to a vertical perfusion rig (Hugo Sachs 
Elektronik-Harvard Apparatus GmbH, Germany). This allowed retrograde perfusion 
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of the heart. The heart was perfused at 80 mmHg with Krebs-Henseleit solution (in 
mM: 118 NaCl, 4.7 KCl, 2 CaCl2, 1.2 KH2PO4, 1.2 Mg2SO4, 2 Sodium Pyruvate, 24.9 
NaHCO3, and 10 glucose, pH 7.45, aerated with 95% O2, 5% CO2), heated to 37qC, 
and filtered through an in-line 0.45 Pm Sterivex HV filter (Millipore A/S, Hellerup, 
Denmark). Coronary flow was measured using an ultrasonic flow meter probe 
(Transonic Systems Inc., Ithaca, USA) situated above the aortic cannula. Aortic 
pressure, coronary flow, ECG, and perfusate temperature were continuously 
monitored. Coronary flow was measured using a 16-channel PowerLab system 
(ADInstruments, Oxford, UK) and recorded by LabChart 7 software. The heart was 
left until the basal coronary flow had stabilised before any drugs were added to the 
perfusate. 
 
Single cell electrophysiology. Single smooth muscle cells were isolated from LAD 
coronary arteries by enzymatic treatment. The dissected vessel was placed into ice 
cold, Ca2+-free dispersal PSS (in mM: NaCl 120, KCl 6, Glucose 12, HEPES 10, 
MgCl2 1.2, pH adjusted to 7.4 with NaOH). The solution was then supplemented with 
1.75 mg/ml Collagenase IA, 0.9 mg/ml Protease X, 1 mg/ml BSA, and 1 mg/ml 
Trypsin inhibitor and incubated at 37qC for 9 minutes. Following this, the vessels was 
washed with ice cold dispersal PSS 3 times. After the last wash, the tube was filled 
with 1 mL of dispersal PSS and the vessel was triturated with a fire-polished, wide-
bore Pasteur pipette to liberate the VSMCs mechanically. The resultant cell 
suspension was then supplemented with CaCl2 to 0.75mM and plated onto 
coverslips before being left to settle at 4qC before use. 
Whole cell currents were recorded following amphotericin B permeabilization (300 
µg/ml) in the absence and presence of 10 mM caffeine. Amphotericin was added to 
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the pipette solution (in mM: CsCl 106, TEA-Cl 20, HEPES 10, EGTA 10, pH adjusted 
to 7.2 with CsOH), which was refreshed every two hours for consistent Amphotericin 
activity. The cells were superfused with bathing solution (in mM: NaCl 120, TEA-Cl 5, 
KCl 6, glucose 12, HEPES 10, MgCl2 1.2, CaCl2 1.5, pH adjusted to 7.4 with NaOH). 
Currents evoked by caffeine application were recorded during a ramp protocol which 
stepped to -100 mV from a -50 mV holding potential, and steadily increased to +100 
mV over 2 seconds. MONNA was applied in the caffeine-free bathing solution before 
the protocol was repeated in the presence of both drugs. Where possible, drugs 
were applied while recording from the same cell as the initial caffeine application. 
Cells were always compared to same day controls. Similar experiments were 
performed on pulmonary artery cells where ICl(Ca) has been characterised extensively 
(Manoury et al., 2010; Pritchard et al., 2014). 
 
Statistical Analysis and Blinding: For all graphs the error bars represent standard 
error of the mean (SEM) of no less than 5 independent data points. Each data point 
represents data collected from one animal. Data from myography experiments are 
expressed as a percentage of the peak contraction in response to a maximal 
concentration of U46619 or 5HT, or the peak of the first high K+-induced 
contraction/EC80-induced contraction. This is to control for variation in the overall 
contractility of the vessel segment. Similarly, in the Langendorff experiments, data is 
expressed as percentage change in flow to control for varying heart sizes and 
therefore innate differences in coronary flow. Randomisation of samples was 
undertaken in the functional experiments by scrambling the vessel segments before 
mounting them into the myograph chambers. In this way vessel segments from 
higher or lower down the coronary artery branch were randomised to whether they 
  
 
This article is protected by copyright. All rights reserved. 
were subjected to treatment or control conditions. Blinding of the experiments was 
impractical due to the experimenter adding differing concentrations of drugs to the 
set-ups. Concentration effect curves were log transformed to reduce the skew and 
curves were fitted to the data using four-parameter, non-linear regression curve 
fitting in GraphPad Prism (version 7.0b) (GraphPad Prism, RRID:SCR_002798) 
 with the following formula: Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-X)*HillSlope)) where 
x is [agonist] (in log M), Y is the percentage of the peak contraction mentioned 
above, Top refers to Fmax (maximal percentage), Bottom refers to Fmin (average 
percentage contraction at lowest concentration of agonist), and the Hill Slope is 
variable. Comparisons of responses ± blocker vs same-day/animal controls were 
compared by two-way analysis of variance (ANOVA), followed by a post hoc test 
(Bonferonni) for multiple comparisons. Peak contraction studies ± inhibitor and ± Cl- 
were compared to same day/animal controls using paired or unpaired Students two-
tailed t-test where appropriate. Comparisons between Wistars and SHRs were made 
using data from earlier experiments in order to reduce animal numbers. Therefore 
data were not paired for analysis and the n numbers are not equal. Statistical 
significance is defined as 3ӈ0.05 (*). Two stars indicate P WKUHH VWDUV - 
PIRXr stars - P 
 
Reagents: All drugs and reagents were purchased from Sigma-Aldrich (Dorset, UK) 
unless otherwise stated. MONNA, T16Ainh-A01, and Ani9 (Tocris, UK) block Cl- 
currents generated by the over-expression of TMEM16A, or endogenous TMEM16A 
currents with IC50s of about 0.1, 1, and 0.1 µM, respectively (Namkung et al., 2011; 
Oh et al., 2013; Seo et al., 2016). 
 
  
 
This article is protected by copyright. All rights reserved. 
Nomenclature of Targets and Ligands  
Key protein targets and ligands in this article are hyperlinked to corresponding 
entries in http://www.guidetopharmacology.org, the common portal for data from the 
IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018), and are 
permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 
(Alexander et al., 2017). 
 
Results 
TMEM16A is Expressed in Rat Coronary Arteries: 
Quantitative PCR revealed expression of TMEM16A, and extremely low expression 
of the close orthologue TMEM16B in LAD and septal coronary arteries (figure 1A). 
The relative level of TMEM16A expression was higher than mesenteric arteries but 
lower than pulmonary arteries (figure 1B) where CaCCs have been well 
characterised (Angermann et al., 2012; Davis et al., 2013; Greenwood et al., 2001; 
Greenwood et al., 2004; Manoury et al., 2010; Piper & Large, 2003; Piper & 
Greenwood, 2003; Pritchard et al., 2014; Wang et al., 1992; Wiwchar et al., 2009; 
Yuan, 1997). In Western blot studies (figure 1C), untransfected and GFP-tagged 
TMEM16A transfected HEK293 cells were used to further validate anti-TMEM16A 
antibody AB53212 for use in immunocytochemical/histochemical experiment. Rat 
pulmonary artery lysates were also used as the expression of TMEM16A has 
previously been characterised here (Pritchard et al., 2014; Sun et al., 2012). 
Antibody AB53212 produced a band close to the theoretical molecular weight for 
TMEM16A (~120 kDa) in lysates from rat pulmonary artery and the two HEK cell 
samples. A band was also detected around 145 kDa in lysates of HEK cells 
transfected with GFP-tagged TMEM16A. No band was detected at these molecular 
  
 
This article is protected by copyright. All rights reserved. 
weights from rat coronary artery (n=3 complete isolations, where each isolation 
consisted of 3 rats worth of arteries). The distribution of TMEM16A encoded protein 
was investigated in isolated coronary artery smooth muscle cells. Figure 1D shows 
representative images of TMEM16A staining. Imaging of cells incubated with the 
TMEM16A antibody AB53212 (figure 1D i-iv) showed disperse TMEM16A staining 
throughout the cytoplasm with more intense punctate regions both centrally and 
around the extremities of the cell (examples indicated by arrows 1 and 2). 
Expression of TMEM16A protein was also observed in transverse sections of 
coronary arteries in situ (fig 1E) delineated by Į-smooth muscle actin staining 
(indicated by arrow 1 and 3). TMEM16A was also detected in the surrounding, 
troponin-positive myocardium. 
These data show that TMEM16A is expressed in coronary artery SMCs. 
 
TMEM16A Activation is Integral to Agonist-Induced Contraction of Rat 
Coronary Arteries 
When LAD coronary artery segments were incubated in a low chloride physiological 
saline solution (LCPSS), contractions to both U46619 and 5HT were reduced 
considerably (figures A and B, respectively). Bathing LAD coronary artery segments 
in high K+-PSS produced robust and reproducible contractions that were not affected 
by incubation with  ȝPRO/ MONNA (figure 3C) suggesting the agent did not 
directly inhibit VGCCs. Application of U46619 and 5HT produced concentration-
dependent contractions with approximate EC50 values of 37±7 nmol/L (n=27) and 
207±56 nmol/L (n=12), respectively. These contractions were abolished by prior 
incubation with 10 nmol/L nicardipine (figure S1) indicating that activation of VGCCs 
was crucial for contractions brought about by both U46619 and 5HT. Application of 
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MONNA inhibited the contractile response to U46619 and 5HT in a concentration 
dependent manner (figures 3D and E, and F and G). The inhibitory effect of MONNA 
was not reliant upon a functional endothelium (figures 3I and J) and was not altered 
by incubation with a cocktail of K+ channel blockers (figure H).  
 
Effect of T16Ainh-A01 and Ani9 on Contraction of LAD Coronary Arteries 
High K+-induced contractions of LAD coronary artery segments were significantly 
inhibited by pre-incubation with ȝPRO/ T16Ainh-A01 (figure 3B). While 3 ȝPRO/ 
T16Ainh-A01 and Ani9 did not cause statistically significant attenuations in the high 
K+-induced contractions, there was a trend for high K+-induced  (figures 3B and A 
respectively). In further experiments, Ani9 caused a small, but significant attenuation 
in the U46619-induced contraction although, given the data in figure 3A, it is difficult 
to say whether this was due to TMEM16A inhibition (figure 3C). T16Ainh-A01 caused 
leftward shifts in the U46619 concentration-effect curves in LAD coronary artery 
segments at both 3 and 10 ȝPRO/ (figures 3D and E). Interestingly, the effect of pre-
incubation with 3 ȝPRO/ T16Ainh-A01 was more marked that with 10 ȝPRO/ T16Ainh-
A01 and 3 ȝPROL Ani9. 10 ȝPRO/ T16Ainh-A01 also caused an inhibition of 5HT-
induced contractions in LAD coronary arteries. This inhibition of U46619- and 5HT-
induced contractions with 10 ȝPRO/ T16Ainh-A01 was also seen in septal coronary 
arteries (figure S2). Given the data in figures 2 C-J where MONNA did not cause an 
effect on the high K+-induced contractions, and its effect on agonist-induced 
contractions was independent of endothelium, and was unchanged in the present of 
a cocktail of potassium channel blockers, we decided to use MONNA for further 
studies.  
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Involvement of TMEM16A in coronary perfusion 
The influence of TMEM16A channels on coronary blood flow in whole hearts was 
investigated using a Langendorff preparation. Application of either MONNA or 
T16Ainh-A01 (10 nmol/L ± 1 ȝmol/L) enhanced coronary flow (figure 2A) without any 
effect on cardiac parameters. The QT and RR intervals recorded during these 
experiments can be seen in tables 2 and 3. MONNA (1 ȝmol/L) also prevented the 
decreased coronary flow produced by infusion of the thromboxane A2 receptor 
agonist U46619 (10 nmol/L, figure 4B and C). These data show that 
pharmacologically disabling TMEM16A improves coronary blood flow. 
 
MONNA Attenuates Caffeine-Evoked Chloride Currents in Coronary Artery 
VSMCs and Decreases Membrane Potential of U46619-Constricted Coronary 
Arteries 
In line with previous studies investigating CaCCs (Greenwood et al., 2001), caffeine 
was used to mobilise Ca2+ from the sarcoplasmic reticulum and evoke ICl(Ca). 
Reproducible caffeine-evoked chloride currents were recorded in LAD coronary 
artery VSMCs in the absence, but not in the presence of, 10 µmol/L MONNA (figure 
5A). Caffeine produced considerably larger, faster inward currents in these cells at -
50 mV (Fig 5A). Similar results were seen in experiments carried out on pulmonary 
artery smooth muscle cells (figure S3). In sharp microelectrode recordings on whole 
LAD coronary arteries application of an EC50 concentration of U46619 contracted 
arteries with an associated depolarisation of the membrane potential (Figure 5B). 
Application of 10 µmol/L MONNA caused membrane potential repolarisation (figure 
5B). This change in membrane potential was accompanied by a simultaneous 
decrease in wall tension. 
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Altered Expression of TMEM16A in SHR Coronary Artery SMCs 
SMCs were isolated from coronary arteries as described above. The cleanliness of 
the SMC preparation was confirmed by qPCR analysis of cardiac- and endothelial 
cell-specific markers (troponin T2 (Tnnt2), troponin I3 (Tnni3), Von Willebrand Factor 
(Vwf), and platelet and endothelial cell adhesion marker (Pecam). Tmem16a 
expression was greatest in the SMC sample and at low levels in ventricular tissue 
and endothelial cells. The SMC samples were highly positive for the smooth muscle 
markers alpha smooth muscle actin (Acta2), and myosin heavy chain 11(Myh11),  
while comparatively negligible levels of expression of the cardiac and endothelial 
cell-specific markers were found in the SMC sample. All data for these experiments 
can be found in the supplement (Figure S4). This established that the SMC sample 
was free from cardiac and endothelial contamination. QPCR analysis showed a 
~four-fold increase in expression of TMEM16A in the coronary artery SMCs of SHRs 
when compared to Wistar controls (figure 6A). Importantly, TMEM16A expression in 
ventricular tissue, where protein staining can be seen (figure 1Eiii), was not 
increased in the ventricular tissue of SHRs (figure 6B). This finding adds further 
credence to the fact that the results seen in figure 6A are not due to any contribution 
from cardiac myocytes.  
 
Altered Function of TMEM16A in SHR LAD Coronary Arteries 
Functional experiments revealed that LAD segments had a greater sensitivity to 
U46619 and 5HT compared to segments from normotensive rats contracting more in 
response to lower concentrations without a change in the maximal contractile 
response (figure 7C and D respectively). 30 nmol/L 5HT caused a contraction of 0.12 
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± 0.05 mN in LAD coronary artery segments of Wistars while it caused a much 
bigger contraction of 1.23 ± 0.32 mN in those of SHRs (p=0.0018), equivalent to a 
~10 fold increase in contraction. This increased sensitivity was abolished by 
application of 10 µmol/L MONNA (figure 7B). Similar effects were seen in the 
U46619 contraction study (figure 7A). In addition, LAD segments from SHRs 
exhibited a higher level of spontaneously-developed basal tone, which was 
abrogated by 10 µmol/L MONNA (figure 7I). In contrast, the overall contractility of 
LAD coronary artery segments from SHRs in response to U46619 and 5HT was less 
sensitive to inhibition by MONNA than in LAD coronary arteries from normotensive 
rats (figures 7E, F, G and H). This is reflected in the mean EC50 values highlighted in 
table 4. In summary, expression of TMEM16A mRNA is higher in coronary arteries 
from SHRs that was associated with a MONNA-sensitive increase in basal tone and 
responsiveness to low concentrations of U46619 and 5HT. 
 
Discussion 
This study is the first to identify expression of TMEM16A in coronary arteries and 
implicate it in determination of coronary perfusion. In addition, we report changes in 
TMEM16A expression and function in coronary arteries from hypertensive rats. 
We show that MONNA, at concentrations that inhibit TMEM16A mediated Cl- 
currents in over-expression systems, inhibited ICl(Ca) in coronary artery myocytes, 
attenuated contractions produced by U46619 and 5HT, reversed membrane 
depolarisation produced by U46619, inhibited spontaneously induced basal tone and 
improved coronary blood flow. These anti-contractile effects were not dependent 
upon a functional endothelium, nor were they affected by incubation of the coronary 
artery with several K+-channel blockers. Moreover, they did not reflect a direct block 
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of calcium channels as contractions produced by high K+ solutions were not affected 
by MONNA, although two other TMEM16A blockers, T16Ainh-A01 and Ani9, did 
affect high K+ spasms moderately.  Incubation of the coronary arteries in low Cl- 
bathing solution also attenuated 5HT- and U46619-induced contractions 
considerably. These consolidated data provide evidence that activation of 
TMEM16A-comprising Cl- channels produces sufficient depolarisation to increase 
calcium channel opening and produce vasoconstriction in response to two different 
receptor agonists as well as at rest in certain conditions. By inference these data 
implicate TMEM16A channels as key determinants of coronary perfusion. However, 
Boedtkjer et al. (2015) have challenged the specificity of T16Ainh-A01, and to a lesser 
extent, that of MONNA. They reported no difference in contractions of rat mesenteric 
arteries to noradrenaline in the absence or presence of Cl- in the PSS. Moreover, 10 
ȝPRO/L of both T16Ainh-A01 and MONNA inhibited the Cl- independent contraction 
seen in the mesenteric arteries, indicating that these two inhibitors abrogate 
contractility of these vessels in the absence of a functional chloride gradient. Our 
data in coronary arteries concurs with their finding that T16Ainh-A01 relaxed rat 
mesenteric arteries contracted with a high extracellular K+-containing (60 mmol/L) 
saline solution. This supports Boedtkjer et al.¶V (2015) proposal that this agent 
inhibited vasospasm by means other than inhibiting ICl(Ca), with direct blockade of 
calcium channels most likely. However, our data did not emulate the low Cl- 
experiment findings of Boedtkjer et al. (2015) and we have no explanation for these 
differences. Our extensive characterisation of MONNA gave us no reason to doubt 
its specificity for TMEM16A. Nonetheless, it is curious that so many purportedly 
TMEM16A-specific inhibitors also cause a decrease in the high K+-induced 
contraction. Interestingly, a reduction in high K+-induced contraction and expression 
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of VGCCs has been reported upon TMEM16A knockdown in rat mesenteric arteries 
(Dam et al., 2014), and more recently, constitutive TMEM16A-targetted siRNA 
downregulation was associated with a concurrent decrease in L-type voltage-gated 
Ca2+ channel protein expression (Jensen et al., 2018). This questions whether 
T16Ainh-A01 and Ani9 are indeed blocking TMEM16A and causing a similar effect to 
that of TMEM16A knockdown. It could be possible that TMEM16A has a regulatory 
function that modulates other ion channels, as suggested in Jensen et al. (2018). 
CFTR, another Cl- channel, negatively regulates CaCCs in bovine pulmonary 
arteries (Wei et al., 1999). Furthermore, it indicates that TMEM16A could be coupled 
to VSMC contraction in ways other than the direct depolarising effect of ICl(Ca). Indeed 
a recent paper has implicated TMEM16A in the RhoA/ROCK signalling pathway (Li 
et al., 2016). This could possibly account for the results seen in the Cl- free 
experiments in Boedtkjer et al. (2015) in which mesenteric arteries still produce 
TMEM16A-inhibitor sensitive noradrenaline-induced contractions. 
We observed an increase of TMEM16A transcript in coronary and arteries from 
SHRs, which exhibited a greater level of spontaneous basal tone development. 
Furthermore, we show that U46619 and 5HT were more effective at eliciting 
contraction at lower concentrations (10 and 30 nmol/L respectively) in arteries from 
SHRs and these responses along with the heightened basal tone were abrogated by 
MONNA. Interestingly, our study shows that inhibition of TMEM16A was less 
effective against maximal contractions in arteries from SHRs compared to Wistar 
controls, similar to a previous report by Wang et al. (2015). These results suggest 
that the increase in contractility of coronary arteries from SHRs could be due to the 
increased expression of TMEM16A causing greater depolarisation and therefore 
Ca2+ influx. In support of this hypothesis, VSMC specific knockout of TMEM16A 
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reduced systemic blood pressure and attenuated the development of hypertension in 
mice (Heinze et al., 2014) and knockdown of TMEM16A with siRNA prevented the 
increase in systolic blood pressure in SHRs (Wang et al., 2015). Furthermore, 
pulmonary arteries from animals with monocrotaline- or chronic hypoxia-induced 
hypertension have increased TMEM16A protein and ICl(Ca) density (Forrest et al., 
2012; Sun et al., 2012). Ideally, we would like to show increased protein expression 
by Western blot in the coronary arteries of SHRs, similar to studies in other arteries 
of SHRs (Wang et al., 2015). However, we were not able to detect a band at ~120 
kDa in lysates from coronary artery or mesenteric artery even though robust staining 
was detected in immunocytochemical studies with the validated anti-TMEM16A 
antibody, AB53212. These findings suggest that the molecular isoforms of 
TMEM16A may differ in different arteries with the pulmonary artery exhibiting the 
conventional full-length form. A truncated isoform of TMEM16A has been identified in 
the interstitial cells of Cajal of patients with diabetic gastroparesis (Mazzone et al., 
2011) and future studies will focus on the relative abundance of these truncated 
variants over the full-length form in arterial regulation. 
  
As inhibiting TMEM16A improved coronary perfusion then any upregulation in 
expression or activation efficiency would narrow coronary arteries, contributing to the 
development of coronary artery disease. Given the strong association between 
hypertension and coronary artery disease, we suggest that these findings have 
important implications in the pathogenesis of coronary artery disease and that 
targeting TMEM16A may not only prove an effective mechanism to reduce blood 
pressure but also increase coronary artery blood flow and cardiac perfusion. 
Interrogation of a UK Biobank database containing >400,000 individuals identified a 
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novel single nucleotide polymorphism in the coding region of the TMEM16A gene 
that is strongly associated with the pathogenesis of essential hypertension. We 
performed combined annotation dependent depletion (CADD) analysis of all 51 loci 
identified to be associated with essential hypertension in the UK Biobank and found 
that the SNP associated with TMEM16A (rs2186797) was the most deleterious of all 
SNPs associated with hypertension (see table in supplement). CADD prioritises 
functional, deleterious and pathogenic variants across many categories, and CADD 
scores of t20 are predictive of the 1% most deleterious substitutions to the human 
genome. This analysis of the large data set provided by the UK Biobank provides 
powerful support for TMEM16A in the pathogenesis of hypertension, that 
consolidates animal studies with TMEM16A deficient mice (Heinze et al., 2014) and 
the pharmacological or molecular disabling of TMEM16A. Importantly, the caveat 
must be made that the functional impact of the SNP in question on TMEM16A is not 
currently known. Future studies will investigate how this variant may change the 
structure and function of the TMEM16A protein so it is possible to hone in on what it 
is that leads to pathology. The future impact of this could be dramatic if the defect in 
TMEM16A can be rectified pharmacologically. Interestingly, it is not the first time this 
gene variant of TMEM16A has been reported in relation to a cardiovascular 
pathology. Shiffman et al. (2006) found that the allele frequency of the rs2186797 
TMEM16A gene variant was significantly increased in patients with early-onset 
myocardial infarction (Shiffman et al., 2006) - an observation made pertinent by the 
findings of the present study. More recently, a different variant of TMEM16A, 
rs7127129, was identified as being associated with changes in the aortic root 
diameter of patients with heart failure (Wild et al., 2017). Recent investigations have 
resolved the atomic structure of murine TMEM16A transmembrane domains which 
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could facilitate identifying how these SNPs cause functional variation. Given the 
noteworthy CADD score of the rs2186797 variant (>21), the expressional and 
functional changes of TMEM16A in coronary arteries from SHRs outlined above, and 
the other reports of TMEM16A SNPs in cardiovascular disease, as well as previous 
reports of TMEM1$¶VUROH LQDQLPDOPRGHOVRIK\SHUWHQVLRQ WKHUH LVDSOHWKRUDRI
evidence to suggest that irregularities in expression and function of TMEM16A 
contribute to cardiovascular pathology. 
In conclusion, this study provides evidence for an important role of TMEM16A in rat 
coronary arteries under normal physiological circumstances, but also in the 
pathophysiology of hypertension. Future studies will help clarify the role of 
TMEM16A in the vasculature and in cardiovascular diseases, not only as an ion 
channel regulating ICl(Ca), but also as a multifunctional protein, which may modulate 
the function of other ion channels. Furthermore, investigations of the functional 
impact of the SNP in the TMEM16A coding region could help to elucidate how this 
SNP contributes to the pathology of hypertension in humans. 
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Table 1. Primer sequences used in qPCR experiments. 
 
Gene )RUZDUG3ULPHUV¶-¶ Gene ID Amplicon 
size (base 
pairs) 
Reverse Primers (-¶-¶ 
TMEM16A CCCTGTTCGTTGCGTCCTT NM_001107564 121 
GCTCTGATGGCTACTGGTCTC 
Tmem16b GGACGATGAGGATGATGAAGATAA XM_017602863.1 
 
128 
GATAGACAATGACCCCAAAGACA 
Myh11 CAGTTGGACACTATGTCAGGGAAA XM_017596998.1 
 
78 
ATGGAGACAAATGCTAATCAGCC 
Acta2 ATCCGATAGAACACGGCATC NM_031004.2 
 
228 
AGGCATAGAGGGACAGCACA 
Tnni3 TGACCTGCGTGGCAAGTT NM_017144.2 
 
153 
TCCTTCTCAATGTCCTCCTTCT 
Tnnt2 AGGAGGAAGGCTGAAGATGA XM_006249842.3 
 
126 
CTCTCGCTCTGTCTGTCTCT 
Pecam1 CTCCTAAGAGCAAAGAGCAACTTC NM_031591.1 
 
100 
TACACTGGTATTCCATGTCTCTGG 
Vwf GTCGGAAGAGGAAGTGGACATT NM_053889.1 
 
136 
GGGCACACGCATGCGCTCTGTA 
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Table 2. Cardiac parameters from Langendorff experiments. QT and RR intervals 
were extrapolated from ECG recorded by LabChart. Coronary flow was measured 
directly with ultrasonic flow meter probe. Data is expressed as mean±SEM, n=5-6. 
Paired t-test. *P < 0.05 from vehicle. #P < 0.05 from U46619.  
 
Treatment QT (ms) RR interval (ms) Coronary flow 
(ml/min) 
Vehicle 64±9 174±20 9.9±0.1 
T16Ainh-A01 (µM) 
  
  0.01 62±7 168±19 9.9±0.1 
  0.03 65±9 179±21 10.2±0.1 
  0.1 73±8 174±21 10.2±0.2 
  0.3 72±8 166±22 11.1±0.3* 
  1 64±8 151±28 12.9±0.3* 
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Table 3. Cardiac parameters from Langendorff experiments. QT and RR intervals 
were extrapolated from ECG recorded by LabChart. Coronary flow was measured 
directly with ultrasonic flow meter probe. Data is expressed as mean±SEM, n=5. 
Paired t-test. *P < 0.05 from vehicle.  
 
 
  
Treatment QT (ms) RR interval (ms) Coronary flow 
(ml/min) 
Vehicle 69±6 182±18 11.9±0.1 
MONNA (µM) 
  
  0.01 66±7 166±15 12.1±0.2 
  0.03 72±8 182±15 12.2±0.2 
  0.1 63±5 173±17 12.8±0.4 
  0.3 64±6 176±20 14.3±0.4* 
  1 74±8 191±20 20.7±1.0* 
Vehicle 72±7 173±14 12.4±0.6 
U46619 (µM) 
   
  0.01 62±5 167±17 8.8±0.2* 
MONNA + U46619 (µM)   
  1.0 + 0.1 66±8 177±19 11.6±0.2# 
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Table 4. Mean EC50s of U46619 and 5HT in coronary arteries from Wistar and 
spontaneously hypertensive rats in the presence and absence of different 
concentrations of the TMEM16A-specific inhibitor MONNA. 
 
 
  
DMSO 1 PM MONNA 10 PM MONNA 
U46619 EC50 rS.E.M (nM) 
NT 50.1r8 172.7r32 167.1r234 
SHR 30.0r5 31.2r86 145.5r73 
5HT(nM) (rS.E.M) 
NT 258.2r82 254.9r67 415.1r213 
SHR 73.3r10 167.0r28 107.7r37 
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Figure 1. TMEM16A is expressed in rat coronary arteries. (A) Abundance of 
TMEM16A and TMEM16B mRNA relative to predetermined house-keeping genes in 
LAD and septal coronary arteries. n=3 where n is a pooled sample of arteries from at 
least 3 rats. (B) Abundance of TMEM16A mRNA relative to predetermined house-
keeping genes in LAD coronary arteries, mesenteric arteries, and pulmonary 
arteries. n=3 where n is a pooled sample of arteries from at least 3 rats. (C) Western 
blot with anti-TMEM16A antibody AB53212 on lysates from rat pulmonary artery, 
TMEM16A-GFP-transfected HEK293 cells, and un-transfected HEK293 cells. Each 
rat sample constitutes 3 rats worth of tissue.  (D) Single isolated VSMCs from LAD 
coronary arteries with anti-TMEM16A antibody AB53212 (i-iv). Cells are co-stained 
with anti-D smooth muscle actin (i and v), DAPI (ii and vi), anti-TMEM16A (iii), and a 
composite image (iv and viii). Arrows highlight small hotspots of intense staining. 
Images v-viii show a single VSMC isolated from a LAD coronary artery that was not 
incubated with an anti-TMEM16A primary antibody. Images are representative of at 
least 3 cells from arteries of 3 rats. ScalHEDULVȝP(,PDJHVRIDȝPWKLFN
slice of a rat where a coronary artery can be seen in situ, stained with anti-D smooth 
muscle actin (i and v), DAPI (ii and vi), +anti-TMEM16A (iii), -anti-TMEM16A (vii), 
and a composite image (iv and viii). Arrows 1 and 3 indicate the arterial wall within 
the myocardial tissue and arrow 2 highlights the lumen of the vessel. Images are 
representative of slices from 2 rats and 2-3 arteries per rat. ScaOHEDULVȝP 
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Figure 2. Inhibition of TMEM16A significantly attenuates coronary artery function. 
Bar charts showing that contractions of coronary arteries to U46619 (A) and 5HT (B) 
were significantly smaller when the segments were bathed in LCPSS; n=7 for 
U46619 and n=6 for 5HT. (C) Pre-incubation of 10 ȝPRO/MONNA had no effect on 
the KPSS-induced contraction in LADCA segments; n=6 for both DMSO and 
MONNA. (D) Pre-LQFXEDWLRQZLWKȝmol/L MONNA caused a significant attenuation 
of the U46619-induced response in LAD coronary arterials segments (n=8 for both 
DMSO and 1 ȝPRO/ MONNA), while pre-LQFXEDWLRQ RI  ȝmol/L MONNA 
significantly reduced the ability of the vessel to contract to U46619 (E) (n=8 for both 
DMSO and 10 ȝPRO/MONNA). (F) Pre-incubation ZLWKȝmol/L MONNA did not 
cause a significant attenuation of the 5HT-induced response in LAD coronary arterial 
segments (n=6 for both DMSO and 1 ȝPRO/ MONNA), while pre-incubation of 10 
ȝmol/L MONNA significantly reduced the ability of the vessel to contract to 5HT (G) 
(n=8 for both DMSO and 10 ȝPRO/ MONNA). (H) Concentration-effect curves of 
U46619 in LADCA segments in the presence of K+ channel blockers were 
significantly attenuated after incubation with 10 ȝPRO/ MONNA; n=8 for both. (I) 
Scatter graph indicating that the EC50 of U46619 in LAD coronary artery segments in 
the presence of 10 ȝPRO/ MONNA were similar in both endothelium intact, and 
denuded segments. Data are expressed as mean EC50 of U46619 ± S.E.M (in 10 
ȝPRO/), n=5 for both. (J) The maximal contraction evoked by U46619 in LADCA 
segments incubated with 10 ȝPRO/MONNA was not different between endothelium 
intact and endothelium denuded segments; n=5 for both. All data are expressed as 
mean ± S.E.M. Statistical significance is defined as 3ӈ0.05 (*). ** indicates P
*** - P**** - P  
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Figure 3. Effect of other TMEM16A inhibitors on coronary artery contractility. (A) 
Pre-incubation with 3 ȝPRO/ Ani9 did not cause significant attenuation of the high 
K+-induced contraction of coronary arteries (n=5 for both DMSO and 3 ȝPRO/ Ani9). 
(B) While pre-incubation of 3 ȝPRO/ T16Ainh-A01 did not cause a significant 
attenuation of high K+-induced contraction of coronary arteries (n= 5 for both DMSO 
and 3 ȝPRO/ T16Ainh-A01), pre-incubation with 10 ȝPRO/ T16Ainh-A01 reduced the 
contractility considerably (n=12 for both DMSO and 10 ȝPRO/ T16Ainh-A01). (C) 
U46619 concentration effect curves were significantly attenuated in the presence of 
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3 ȝPRO/ Ani9 (n=6 for both DMSO and 3 ȝPRO/ Ani9), 3 ȝPRO/ T16Ainh-A01 (D) 
(n=9 for both DMSO and 3 ȝPRO/ T16Ainh-A01), and 10 ȝPRO/ T16Ainh-A01 (E) 
(n=10 for both DMSO and 10 ȝPRO/ T16Ainh-A01). (F) 5HT concentration effect 
curves were also significantly impaired in the presence of 10 ȝPRO/ T16Ainh-A01 
(n=7 for both DMSO and 10 ȝPRO/ T16Ainh-A01). All data are expressed as mean ± 
S.E.M. Statistical significance is defined as 3ӈ0.05 (*). ** indicates P *** - 
P**** - P 
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Figure 4. Inhibition of TMEM16A significantly increases coronary flow. (A) 
Application of MONNA and T16Ainh-A01 caused a concentration-dependent increase 
in coronary flow (n=6 for MONNA, n=5 for T16Ainh-A01, and n=5 for DMSO). Pre-
incubation with 1 ȝPRO/ MONNA prevented U46619-induced reductions in coronary 
flow (B) (n=5 for both conditions). C shows a representative trace from the 
experiment described in B. All data are expressed as mean ± S.E.M. Statistical 
significance is defined as 3ӈ0.05 (*). ** indicates P *** - P **** - 
P 
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Figure 5. The scatter plot shows the increase in current evoked from LAD coronary 
artery VSMCs, at a holding potential of -50 mV, upon application of 10 mmol/L 
Caffeine in the absence and presence of 10 ȝPRO/ MONNA; n=5. Scatter graph 
showing the membrane potential (left, mV), and evoked contraction (right, mN) in 
resting, +U46619, and +U46619+10 ȝPRO/MONNA; n=4 for resting EM, n=6 for EM 
in U46619, and n=7 for EM in U46619+10 ȝPRO/ MONNA, and n=7 for tension 
recordings in resting and U46619, and n=8 in U46619+10 ȝPRO/MONNA. All data 
are expressed as mean ± S.E.M. Statistical significance is defined as 3ӈ0.05 (*). ** 
indicates P*** - P**** - P 
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Figure 6. Increased expression of TMEM16A in coronary arteries from 
spontaneously hypertensive rats. (A) TMEM16A mRNA is expressed at levels 
approximately four-fold greater in coronary arteries SMCs from SHRs when 
compared to Wistar rats. There was no increase in TMEM16A expression in the 
ventricular tissue from SHRs. (B) The expression of the cardiac-specific marker 
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troponin I3 (Tnni3), was expressed at negligible levels in the coronary artery SMC 
samples of both Wistar rats and SHRs, and expression was significantly greater in 
the ventricular tissue of the same rats (* for Wistar tissues, # for SHR tissues). All 
data are expressed as mean ± S.E.M of at least 5 separate rat samples. Statistical 
significance is defined as 3ӈ0.05 (*). ** indicates P *** - P **** - 
P 
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Figure 7. Altered function of TMEM16A in LAD coronary arteries from spontaneously 
hypertensive rats. (A) Increases in contractility of LAD coronary arteries from SHRS 
in response to lower concentrations of U46619 (n=8 for Wistar and n=6 for SHRs) 
and 5HT (B) (n=9 for Wistars and n=7 for SHRs) were abolished by pre-incubation 
ZLWKȝPRO/0211$/$'FRURQDU\DUWHULHV IURP6+5VZHUHPRUHVHQVLWLYH WR
constriction with U46619 (n=27 for Wistar and n=16 for SHR) and 5HT (n=12 for 
Wistar and n=13 in SHRs) (C and D). (E) Pre-incubation with 1 ȝPRO/MONNA has 
no effect on the U46619 concentration-effect curve in LAD coronary artery segments 
of SHRs. (F) Pre-incubation with 10 ȝPRO/ MONNA significantly attenuates the 
ability of the vessel to constrict to U46619. (G) Pre-incubation with 1 ȝPRO/MONNA 
has a small but significant effect on the 5HT concentration-effect curve in LAD 
coronary artery segments of SHRs. (H) Pre-incubation with 10 ȝPRO/ MONNA 
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significantly attenuates the ability of the vessel to constrict to 5HT. (I) Basal tone 
developed in LAD coronary artery segments of SHRs was significantly suppressed 
by application of 10 ȝPRO/ MONNA. All data are expressed as mean ± S.E.M. 
Statistical significance is defined as 3ӈ0.05 (*). ** indicates P *** - P
**** - P 
 
 
